Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Thymalin is not a single peptide but a polypeptide complex extracted from the thymus glands of young cattle. The mixture contains multiple low-molecular-weight peptides; published work by the Khavinson group has identified at least two short bioactive components — the dipeptides Lys-Glu (KE) and Glu-Trp (EW) — as significant contributors to the preparation's reported activity. Synthetic forms of those individual dipeptides are sold separately under trade names such as Vilon (KE) and Thymogen (EW).
The original extract was developed and standardized in the early 1970s by Vyacheslav Morozov and Vladimir Khavinson at the Military Medical Academy in what was then Leningrad.
History
The Khavinson group developed thymalin alongside several other organ-derived "polypeptide bioregulators" — most notably epithalamin (from the pineal gland) and prostatilen (from the prostate). The work was rooted in the Soviet concept of "peptide bioregulators" — the idea that tissue-specific short peptides could exert organ-restoring effects across systems. Clinical introduction in the Soviet Union occurred in the early 1980s under standard Soviet drug-registration procedures.
Trials reported through the 1980s and 1990s described thymalin as improving immune parameters in post-surgical recovery, infectious complications, burns, and age-related immune decline. The 2002 Khavinson and Morozov paper reported reductions in 6-year mortality in elderly cohorts treated with thymalin and epithalamin compared with untreated controls — though the trial methodology has not been replicated outside Russia.
In 2020, a Bulletin of Experimental Biology and Medicine paper reported that thymalin promoted hematopoietic stem cell differentiation in cell culture. During the COVID-19 pandemic the same group published work on the dipeptide components in the context of pulmonary inflammation.
Regulatory status
Thymalin is approved in Russia and several other post-Soviet states for immunomodulation in post-surgical recovery, infectious complications, and age-related immune decline. It is not approved in the United States, the European Union, the United Kingdom, Canada, Japan, or Australia. The compound has not been the subject of an FDA new drug application, and as a multi-component extract it does not fit the FDA's 503A bulk substances framework. US compounding pharmacies cannot legally prepare it.
The World Anti-Doping Agency has not specifically listed thymalin, but as a non-approved peptide preparation it would fall under WADA's S0 (non-approved substances) category in competition.
How researchers describe its action
Because thymalin is a multi-component extract, no single binding site has been characterized. The published mechanism papers describe several proposed effects:
- Restoration of T-cell maturation in models of immune deficiency, particularly in cells that have lost thymic input due to age or stress.
- Modulation of cytokine balance, with reports of increased interleukin-2 and decreased pro-inflammatory cytokines in treated subjects.
- Gene expression effects of the dipeptide components — KE and EW have been studied as direct regulators of certain transcriptional programs related to immunity and hematopoiesis.
The published mechanism work has not been independently replicated outside the Khavinson group. The molecular targets remain uncertain.
Half-life and dosing intervals
The published pharmacokinetic data for thymalin is limited, and because the preparation is a mixture, a single half-life value is not meaningful. The dipeptide components are cleared from circulation rapidly — within minutes — but the labeled clinical effect persists over days, similar to thymosin alpha-1.
The Russian product label specifies intramuscular administration. The typical course is 5 to 10 mg per day, intramuscularly, for 5 to 10 consecutive days, with repeat courses every 1 to 6 months as part of an immunomodulation regimen. Subcutaneous injection is not the labeled route in the approved package insert.
Reconstitution example
The licensed Russian product is supplied as a 10 mg lyophilized powder in single-use vials with a 2 mL saline diluent for intramuscular use. Research-grade thymalin is similarly supplied lyophilized in 5 mg or 10 mg vials.
A 10 mg vial reconstituted with 2 mL of saline or bacteriostatic water yields 5 mg/mL. On a 1 mL syringe, 1 mL contains 5 mg — the lower end of the labeled daily intramuscular dose. Vial's calculator handles the mass-to-volume conversion automatically.
What to know
- Approved only in Russia and a few post-Soviet states. Outside that region, thymalin has no approved use and no validated supply chain.
- A mixture, not a defined peptide. Thymalin is a multi-component extract; lot-to-lot consistency depends entirely on the manufacturer's standardization.
- Intramuscular by label. The Russian package insert specifies intramuscular dosing. Subcutaneous administration is not in the labeled route.
- Independent replication is limited. Most published research comes from the Khavinson group; independent Western trials are scarce.
- Banned in competition. As a non-approved peptide preparation, thymalin falls under WADA's S0 category in competitive sport.
- Storage. Lyophilized vials are stable refrigerated and protected from light. Once reconstituted, use promptly per the package insert.
Sources
- 1.Morozov VG, Khavinson VK. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology.
- 2.Khavinson VKh, Morozov VG. (2002). Geroprotective effect of thymalin and epithalamin. Advances in Gerontology.
- 3.Khavinson VK et al. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of Experimental Biology and Medicine.
- 4.Linkova N et al. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences.